BR0002957A - Combinações de inbidores de aldose-redutase e inibidores de ciclooxigenase-2 seletivos - Google Patents

Combinações de inbidores de aldose-redutase e inibidores de ciclooxigenase-2 seletivos

Info

Publication number
BR0002957A
BR0002957A BR0002957-2A BR0002957A BR0002957A BR 0002957 A BR0002957 A BR 0002957A BR 0002957 A BR0002957 A BR 0002957A BR 0002957 A BR0002957 A BR 0002957A
Authority
BR
Brazil
Prior art keywords
inhibitors
aldose reductase
prodrug
combinations
diabetic
Prior art date
Application number
BR0002957-2A
Other languages
English (en)
Inventor
Banavara Lakshman Mylari
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0002957A publication Critical patent/BR0002957A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Patente de Invenção: <B>"COMBINAçõES DE INIBIDORES DE ALDOSE-REDUTASE E INIBIDORES DE CICLOOXIGENASE-2 SELETIVOS"<D>. Esta invenção está dirigida a métodos, composições farmacêuticas e kits compreendendo um inibidor de aldose-redutase (ARI), uma sua pró-droga ou um sal farmaceuticamente aceitável do referido ARI ou da referida pró-droga e um inibidor de COX-2 seletivo, uma sua pró-droga ou um sal farmaceuticamente aceitável do referido inibidor de COX-2 seletivo ou da referida pró-droga. Esta invenção diz ainda respeito a métodos de utilização daquelas composições farmacêuticas para o tratamento de complicações diabéticas tais como neuropatia diabética, nefropatia diabética, retinopatia diabética e cardiomiopatia diabética.
BR0002957-2A 1999-06-30 2000-06-30 Combinações de inbidores de aldose-redutase e inibidores de ciclooxigenase-2 seletivos BR0002957A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14169599P 1999-06-30 1999-06-30

Publications (1)

Publication Number Publication Date
BR0002957A true BR0002957A (pt) 2001-01-30

Family

ID=22496808

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0002957-2A BR0002957A (pt) 1999-06-30 2000-06-30 Combinações de inbidores de aldose-redutase e inibidores de ciclooxigenase-2 seletivos

Country Status (5)

Country Link
US (1) US6555540B1 (pt)
EP (1) EP1064965A3 (pt)
JP (1) JP2001031569A (pt)
BR (1) BR0002957A (pt)
CA (1) CA2313063A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413965B1 (en) * 1999-06-30 2002-07-02 Pfizer Inc. Compositions and treatment for diabetic complications
US6426341B1 (en) * 1999-06-30 2002-07-30 Pfizer Inc. Treatment for diabetic complications
AR030346A1 (es) 2000-08-14 2003-08-20 Alcon Inc Metodo de tratamiento de desordenes neurodegenerativos de la retina y cabeza de nervio optico
AU2002236131B2 (en) * 2001-04-30 2005-04-14 Pfizer Products Inc. Combinations of aldose reductase inhibitors and cyclooxygenase-2 inhibitors
US7338969B2 (en) * 2002-03-08 2008-03-04 Quonova, Llc Modulation of pathogenicity
US7335779B2 (en) * 2002-03-08 2008-02-26 Quonova, Llc Modulation of pathogenicity
US20040187111A1 (en) * 2003-02-21 2004-09-23 Eakin William Joseph Content management portal and method for communicating media content
US20070197492A1 (en) * 2003-05-06 2007-08-23 Aldo Ammendola Modulation of Pathogenicity
WO2005049014A1 (en) * 2003-11-18 2005-06-02 Pharmacia Corporation Cox-2 inhibitors for the treatment or prevention of diabetes-related ocular disorders
US20110236394A1 (en) * 2007-11-15 2011-09-29 Universite Laval Methods for the regulation of the prostaglandin f synthase (pgfs) activity of akr1b1 and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4939140A (en) 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
GB2294879A (en) * 1994-10-19 1996-05-15 Merck & Co Inc Cylcooxygenase-2 Inhibitors
US5510368A (en) * 1995-05-22 1996-04-23 Merck Frosst Canada, Inc. N-benzyl-3-indoleacetic acids as antiinflammatory drugs
DE69816047T2 (de) * 1997-03-14 2004-04-22 Merck Frosst Canada & Co, Kirkland (methylsulfonyl)phenyl-2-(5h)-furanone mit sauerstoff-bindung als cox-2-hemmer
IL124236A (en) * 1997-05-05 2003-01-12 Pfizer Pharmaceutical composition for treating or reversing diabetic cardiomyopathy comprising aldose reductase inhibitor
AP869A (en) * 1998-01-05 2000-09-04 Pfizer 2,3-Substituted indole compounds as anti-inflammatory and analgesic agents.
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
WO2000048447A2 (en) * 1999-02-18 2000-08-24 R-Tech Ueno, Ltd. Composition for treatment of external secretion disorders except hypolacrimation
US6413965B1 (en) * 1999-06-30 2002-07-02 Pfizer Inc. Compositions and treatment for diabetic complications
US6426341B1 (en) * 1999-06-30 2002-07-30 Pfizer Inc. Treatment for diabetic complications

Also Published As

Publication number Publication date
JP2001031569A (ja) 2001-02-06
CA2313063A1 (en) 2000-12-30
EP1064965A3 (en) 2003-02-12
EP1064965A2 (en) 2001-01-03
US6555540B1 (en) 2003-04-29

Similar Documents

Publication Publication Date Title
BR0002953A (pt) Composições e tratamento para complicações diabéticas
BR0005765A (pt) Combinação de inibidores de aldose redutase e agentes anti-hipertensivos para o tratamento de complicações diabéticas
ECSP045520A (es) Metodos de tratamiento con inhibidores de la ptec y agentes antihipertensivos
BR0105457A (pt) Combinações terapêuticas para estimulação do crescimento ósseo
BRPI0617165A2 (pt) Compostos inibidores mek, composições farmacêuticas que os contem e métodos de uso dos mesmos
BRPI0011172B8 (pt) derivados do 4,5-diaril-3(2h)-furanona como inibidores de ciclooxigenase-2
DK1206474T3 (da) Sulfonylphenylpyrazolforbindelser anvendelige som cox-2-inhibitorer
BR0307624A (pt) Inibidores de histona desacetilase
AU2003268156A1 (en) Novel pyrazolopyridine derivatves as pharmaceutical agents
ECSP055783A (es) Derivados de fenilalanina como inhibidores de dipeptidilpeptidasa para el tratamiento o prevención de diabetes
DK1651161T3 (da) Farmaceutiske præparater og fremgangsmåder til at fremme sårheling
AR038207A1 (es) Composicion farmaceutica dispersable oralmente de agomelatina
BR0002957A (pt) Combinações de inbidores de aldose-redutase e inibidores de ciclooxigenase-2 seletivos
BRPI0410727A (pt) composto, composição farmacêutica, e, uso de um composto
BR0115783A (pt) Combinação de agonistas de gaba e inibidores de sorbitol desidrogenase
SV2009003212A (es) Inhibidores de metaloproteasa derivados de heterociclicos ref. prd2727svpct
NO20072258L (no) Farmasøytiske sammensetninger omfattende et camptothecinderivat
SE0101932D0 (sv) Pharmaceutical combinations
PT1325011E (pt) Metodos e compostos para tratamento de doencas proliferativas
DOP2000000022A (es) Combinacion de inhibidores de mtp e inhibidores de hmg-coa reductasa y su uso en medicametos.
BR0002933A (pt) Tratamento para complicações diabéticas
BRPI0412834A (pt) derivados de nicotinamida usados como inibidores da pde4
EP1106184A3 (en) Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications
DK0991424T3 (da) Farmaceutiske præparater omfattende en inhibitor for aldosereduktase og en inhibitor for ACE
BRPI0412694A (pt) compostos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7O, 8O E 9O ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 NA RPI2003 DE 26/05/2009.

B15K Others concerning applications: alteration of classification

Free format text: PROCEDIMENTO AUTOMATICO DE RECLASSIFICACAO. AS CLASSIFICACOES IPC ANTERIORES ERAM: A61K 31/404; A61K 31/41641; A61K 31/422; A61P 3/10.

Ipc: A61K 45/06 (2006.01), A61K 31/353 (2006.01), A61K

Ipc: A61K 45/06 (2006.01), A61K 31/353 (2006.01), A61K